A rare liver cancer that has defeated immunotherapy for years may finally have a weakness. Researchers have discovered that an FDA-approved drug already used for other conditions can restore the immune system's ability to attack fibrolamellar carcinoma, one of the most aggressive forms of liver disease.
Fibrolamellar carcinoma accounts for roughly 2% of all liver cancers but carries a grim prognosis. The disease typically strikes children and young adults and often goes undetected until it has spread throughout the body. Currently, there is no cure, and most patients face severely limited treatment options.
The breakthrough emerged from research showing why this cancer resists immune checkpoint inhibitors, a class of drugs that have revolutionized treatment for melanoma and cancers of the lung, kidney, and bladder. The answer lies in how the tumor's environment physically blocks immune cells from reaching cancer.
How Cancer Hides From the Immune System
Using advanced single-nucleus transcriptomics technology, researchers were able to examine individual cells within tumor tissue and map which genes were active in each one. The analysis revealed that fibrolamellar tumors create a barrier that traps T cells away from cancer cells in what scientists call T-cell exclusion.
The thick fibrous bands that give fibrolamellar carcinoma its name play a central role in this immune evasion. These bands are produced by stellate cells, normal liver cells that become altered when cancer develops. Once changed, the stellate cells send chemical signals that redirect T cells toward the fibrous tissue, effectively locking immune cells out of the tumor's core where they could destroy cancer.
"The picture of the tumor microenvironment began to clear up once we could use this technology," said Andreas Stephanou, a graduate researcher who co-authored the study published in Gastroenterology.
Praveen Sethupathy, a professor at Cornell University who led the research alongside surgical oncologist Venu Pillarisetty of the University of Washington, noted the significance of understanding this mechanism. "Our results provide among the first indications of why immune checkpoint inhibition hasn't worked well in these patients," he said.
The team's work suggests that T-cell exclusion isn't unique to fibrolamellar carcinoma. The same process may explain why pancreatic, prostate, and brain cancers often fail to respond to immunotherapy.
AMD3100, the drug at the center of this research, is already FDA-approved for a blood disorder. Laboratory tests using patient tumor tissue showed the drug successfully guides T cells back into the heart of tumors. When combined with immune checkpoint inhibitors, the effect amplified dramatically, producing a marked increase in tumor cell death.
"A compelling feature of this work is that AMD3100 is already FDA-approved, which can reduce risks and potentially speed up timelines for clinical trials," Sethupathy said.
Researchers are now actively seeking liver cancer specialists to launch human trials testing this combination approach. The fact that AMD3100 carries FDA approval could mean faster pathways to testing and potentially bringing a new treatment option to patients within years rather than decades.
Author Jessica Williams: "The real test comes when this moves from tumor tissue to actual patients, but having an approved drug ready to go changes everything about the timeline and risk calculus."
Comments